Yixin Mass Spectrometry Secures Tens of Millions in Funding to Advance Clinical Mass Spectrometry and Precision Medicine

It is reported that Bioyong Technologies Inc. has recently been approved to receive the Special Fund for Technological Innovation of the Beijing Economic-Technological Development Area (hereinafter referred to as the “Sci-Tech Innovation Fund”). The Sci-Tech Innovation Fund was initiated by the Administrative Committee of the Development Area, is supervised and managed by the Science and Technology Innovation Bureau of the Development Area, and is entrusted to Yizhuang State-owned Capital Investment Holding Co., Ltd. for management.

The Sci-Tech Innovation Fund focuses on providing investment support to enterprises in the development zone, aiming to encourage technological innovation, enhance independent innovation capabilities, promote the transformation of innovative achievements into real productive forces, and facilitate the aggregation of various production factors toward technological innovation and high-end industries.

Bioyong Technologies, established in 2003, is the first company in China dedicated to the research, development, and manufacturing of clinical mass spectrometry systems. In June 2014, its independently developed Clin-ToF time-of-flight mass spectrometry system received medical device certification, making Bioyong the first clinical time-of-flight mass spectrometry enterprise in China to obtain a registration certificate from the China Food and Drug Administration (CFDA). Pioneering globally, the company achieved multi-omics detection on a single platform, enabling one instrument to meet clinical application needs in areas such as microbial identification and nucleic acid testing, with its technology reaching an internationally leading level.

To date, Bioyong Technologies Inc. has established a comprehensive product portfolio encompassing time-of-flight mass spectrometry, triple quadrupole mass spectrometry, and inductively coupled plasma mass spectrometry. Its products support multi-omics technologies, including genomics, proteomics, metabolomics, elementomics, and glycomics, demonstrating significant application potential in precision cardiovascular pharmacotherapy, early diagnosis of Alzheimer’s disease, as well as early cancer screening and guided medication. Currently, the company serves over 80 high-quality clients across China, earning widespread acclaim.

From 2021 to the present, Bioyong Technologies Inc. has been granted 11 invention patents, with a cumulative total of over 200 patent applications filed and more than 60 patents granted. In October 2019, Volume 40, Issue 18 of the *International Journal of Laboratory Medicine* published an article titled “Analysis of Patents and Industry Development for Clinical Detection of Microorganisms by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.” The article pointed out that in the field of clinical mass spectrometry, the number of patent applications and grants held by Bioyong Technologies Inc. far exceeds those of other domestic applicants, indicating that the company has assumed a leading position in mass spectrometry research.

In 2019, the inductively coupled plasma mass spectrometer (Clin-ICP-QMS-I) developed by Bioyong Technologies Inc. received certification from the National Medical Products Administration (NMPA). This instrument features the lowest detection limits, the widest dynamic linear range, minimal interference (via collision/reaction cell mode), high analytical precision, and rapid analysis speed. It not only enables semi-quantitative and quantitative analysis as well as isotope ratio measurements typical of traditional inorganic analytical techniques, but can also be coupled with other technologies such as chromatography and capillary electrophoresis for elemental speciation and distribution analysis. In 2021, the comprehensively upgraded Clin-ICP-QMS-II obtained NMPA certification again, marking a new stage in Bioyong Technologies Inc.’s R&D capabilities in this technical field.

A New Phase, A New Journey. In March 2021, a paper co-authored by Fudan University, the National Center for Protein Sciences, and Chongqing People’s Hospital, which utilized Bioyong Technologies’ mass spectrometry platform for the rapid five-minute detection of COVID-19 via serum peptide fingerprinting, was featured on the cover of a renowned international analytical chemistry journal, attracting widespread attention both domestically and internationally. In July, the research special project established by the Beijing Municipal Science & Technology Commission and jointly undertaken by Bioyong Mass Spectrometry and Peking Union Medical College Hospital successfully passed its defense and acceptance review. This initiative promoted the demonstration and application of various disease detection technologies and achieved the productization of time-of-flight mass spectrometry-based detection techniques across multiple application fields. In September, Bioyong Mass Spectrometry obtained EU CE certification, officially securing the “passport” to access and enter the European market. Meanwhile, in collaboration with Edith Cowan University (ECU) in Australia, Bioyong Mass Spectrometry jointly published a research paper titled “Profile of Immunoglobulin G N-Glycome in COVID-19 Patients: A Case-Control Study” in Frontiers in Immunology. This study elucidated the IgG glycomic profile of COVID-19 patients and compared the differences in IgG glycosylation between COVID-19 patients and healthy individuals.

As a new shareholder of Bioyong Mass Spectrometry, Yizhuang State-owned Capital Investment Holdings stated that the Science and Technology Innovation Fund has historically focused on investing in key industries prioritized for development within the Economic-Technological Development Area, including next-generation information technology, biotechnology and general health, robotics and intelligent manufacturing, and new energy intelligent vehicles. The fund also strategically allocates investments to other emerging strategic industries in alignment with the area’s industrial development plans. As a leading enterprise in the field of domestically produced clinical mass spectrometry, Bioyong Mass Spectrometry is expected to leverage its competitive advantages to contribute to the advancement of precision medicine.

Shareholder SoftBank SAIF Partners stated that the various achievements attained by Bioyong Technologies Inc. in 2021 were commendable. Under the new circumstances, it looks forward to Bioyong’s continued efforts to better leverage its corporate innovation and R&D advantages.

Shareholder Chongde Hongxin pointed out that, as a high-tech enterprise in the biomedical field, Yixin Mass Spectrometry should continue to explore innovative development paths in clinical mass spectrometry amidst the growing prominence of the mass spectrometry industry. It should always uphold the principle that “innovation creates wealth” and generate greater value for safeguarding national welfare and people’s livelihoods.

Bioyong Technologies Inc., established in 2003, is the first company in China dedicated to the research, development, and manufacturing of clinical mass spectrometry systems. In 2006, Dr. Ma Qingwei, the company’s founder and chairman, published a paper titled “MALDI-TOF MS Leads a New Era in Molecular Diagnostics,” spearheading the development of the clinical mass spectrometry industry. In June 2014, the Clin-TOF time-of-flight mass spectrometry system, independently developed and manufactured by the company, received medical device certification from the China Food and Drug Administration (CFDA). As the first domestic enterprise to obtain CFDA registration for a clinical time-of-flight mass spectrometer, Bioyong pioneered and implemented multi-omics detection on a single platform worldwide. This single instrument meets clinical application needs in areas such as microbial identification and nucleic acid testing, with its technology fully reaching international leading standards. In early 2019, the company’s independently developed Clin-ICP-QMS-I also obtained CFDA medical device certification. To date, prominent investment firms including SoftBank SAIF Partners, Beijing Chongde Hongxin, and Hanfu Capital have cumulatively invested over RMB 100 million in Bioyong.

Beijing E-Town International Investment & Development Co., Ltd. (hereinafter referred to as “E-Town Capital”) was established in February 2009. It is a state-owned investment company committed to supporting technological innovation and industrial development in the Beijing Economic-Technological Development Area (hereinafter referred to as the “Development Zone”). As of the end of January 2021, the company’s total assets exceeded RMB 82.5 billion, and its total owners’ equity surpassed RMB 60 billion. The company has several subsidiaries, including E-Town Industrial Investment, E-Town Automotive, E-Town Hong Kong, E-Town Guarantee, E-Town Leasing, E-Town Microfinance, Tongminghu Information City, and Jidian Holdings.

SoftBank SAIF Partners Investment Advisors Ltd. (hereinafter referred to as “SoftBank SAIF Partners”) is an Asia-focused investment firm headquartered in Hong Kong, with branch offices in China, India, and South Korea. The firm currently manages investment funds totaling nearly RMB 6 billion and USD 4 billion. Its China-based team comprises more than 40 professional investment practitioners, all of whom possess strong educational backgrounds from prestigious institutions both domestically and abroad, as well as extensive local work experience. The investment team is characterized by its rich experience, professionalism, diligence, decisive decision-making, and effective execution.

Chongde Hongxin Trust Fund primarily leverages the service functions and industry resources of the Beijing Biotechnology and New Medicine Industry Promotion Center. It maintains close cooperation with relevant government departments, research institutions, renowned universities, pharmaceutical companies, and related organizations and academic groups. The fund is committed to providing comprehensive value-added services to its portfolio companies, including financial support, project application assistance, policy coordination, and market development. Chongde Hongxin focuses on investing in early- to mid-stage innovative enterprises in the biopharmaceutical sector that possess capabilities in original innovation, integrated innovation, and the absorption, digestion, and re-innovation of technologies, striving to cultivate them into high-growth companies with strong profitability.